1.5 Abstract in rivista

1.5 Abstract in rivista: [2363] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 1.201 a 1.220 di 2.363

Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-Cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open-label phase II trial.

2004 Morschhauser, F; Huglo, D; Martinelli, G; Paganelli, G; Zinzani, Pl; Hadjiyiannakis, D; Liberati, Anna Marina; Et, All

Improved safety profile of tumor-targeted taxane: an integrated safety summary of paclitaxel poliglumex (CT-2103) phase 1 and 2 trials

2004 P., Barbieri; F., Oldham; J., Holman; Liberati, Anna Marina

Features of relapsed disease in lymphocyte predominant Hodgkin's disease patients

2005 Liberati, Anna Marina; Cerroni, P; Zanotti, R; Spina, M; Viviani, S; Cervetti, G; Stelitano, C; Ferrara, P; Merluzzi, M; Vitolo, U.

Pre-autologous stem cell transplantation (ASCT) treatment with rituximab does not impair stem cell harvest and engraftment in untreated patients with diffuse large B-cell lymphoma (B-DLCL) at poor prognosis

2005 Botto, B; Vitolo, U; Cortelazzo, S; Chiappella, A; Allione, B; Angelucci, E; Boccomini, C; Cabras, Mg; Ceccarelli, M; Ciccone, G; Di Vito, F; Falchi, L; Guarini, A; Liberati, Anna Marina

Molecular response of CML patients to INF alpha based treatment or to STI based therapy.

2005 Luzi, D; Capozzi, R; Rauco, A; Pace, R; Donti, E; Gottardi, E; Bassetti, A.; Schippa, M; Saglio, G; Liberati, Anna Marina

Ph '-positive (Ph '+) chronic myeloid leukemia (CML) presenting as Ph ' plus T-lymphoblastic lymphoma (LL) resistant to high-dose chemotherapy and Gleevec.

2005 Falchi, L; Desantis, G.; Liberati, F; Pace, R; Morandi, Mg; Scaravaglio, P; Saglio, G; Liberati, Anna Marina

A continous recurrent course in a case of nodular-sclerosis (NS) classical Hodgkin's lymphoma (cHL) associated with Castleman's disease (CD)

2005 Rauco, A; Liberati, F; Capozzi, R; Morandi, Mg; Pace, R; Capparella, V; Cianciulli, M; Liberati, Anna Marina

Has the Ga-67-SPET a role in monitoring Hodgkin and primary mediastinal lymphoma in the PET-FDG age?

2005 Palumbo, Isabella; Desantis, G; Palumbo, Barbara; Falchi, L; Cerroni, P; Capparella, V; Cianciulli, M; Palumbo, R; Liberati, Anna Marina

Effect of adding Rituximab (R) to induction treatment and high dose chemotherapy (HDC) prior to autologous stem cell transplantation (ASCT) as first line therapy in stage III-IV diffuse large B-cell lymphoma (B-DLCL) at poor prognosis

2005 Vitolo, U; Rossi, G; Cabras, Mg; Liberati, Anna Marina

Rituximab-supplemented high-dose sequential chemotherapy (HDS) has superior response rate and event-free survival (EFS) compared to R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: Results from a multicenter randomized GITMO trial.

2005 Ladetto, M; Ricca, I; Benedetti, F; Vitolo, U; Patti, C; Rambaldi, A; Liberati, Anna Marina; Et, All

Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)

2005 F., Morschhauser; D., Huglo; G., Martinelli; G., Paganelli; P., Zinzani; D., Hadjiyiannakis; Liberati, Anna Marina; T., Illidge; N., Milpied; J., Kalmus; P., Morel; U., Reimann; R., Marcus

Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) regimen as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi (gisl)

2005 N. D., Renzo; M., Brugiatelli; A., Montanini; M., Dell'Olio; M., Petrini; C., Stelitano; Liberati, Anna Marina; S., Luminari; S., Morandi; G., Giglio; M., Federico

Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with Rituximab as frontline therapy for high-risk follicular lymphoma (FL) patients: An interim analysis.

2002 Ladetto, M; Ricca, I; Benedetti, F; Vitolo, U; Liberati, Anna Marina; Et, All

Phase II study with Fludarabine and Cyclophosphamide plus Rituximab (FC plus R) in relapsed follicular lymphoma patients

2002 Sacchi, S; Tucci, A; Merli, F; Orsucci, L; Cervetti, G; Occhini, U; Liberati, Anna Marina

Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with rituximab in poor-risk follicular lymphoma: early evaluation on treatment feasibility and response rate

2003 Ladetto, M; Ricca, I; Benedetti, F; Liberati, Anna Marina

Acute myeloid leukemia in the elderly, intensive or maintenance therapy? Our experience in patients over 65 years.

2005 Mettivier, V; Pezzullo, L; Rocco, S; Finizio, O; Bene, L.; De Rosa, C; Nunziata, Gr; Liberati, Anna Marina

Anagrelide treatment and cardiovascular evaluation in 130 patients with essential thrombocythemia (ET): Preliminary report of the Registro Italiano Trombocitemia (RIT).

2005 Gugliotta, L; Tieghi, A; Bulgarelli, S; Tortorella, C; Ciancia, R; Scalzulli, Pr; Cacciola, E; Cacciola, R; Rossi, D; Usala, E; Crugnola, M; Candoni, A.; Giordano, M; Andriani, A; Santoro, C; Vimercati, R; Liberati, Anna Marina; Et, All

Comparative trial of BBR 2778 (pixantrone) plus rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).

2006 Santoro, A; Voglova, J; Gabrail, N; Ciuleanu, T; Liberati, Anna Marina

Rituximab (R) in combination with fludarabine (F) and cyclophosphamide (C) in relapsed follicular lymphoma (FL) patients (pts). Final results of FC plus R phase II trial by the GISL.

2006 Sacchi, S; Pozzi, S; Marcheselli, R; Luminari, S; Federico, M; Tucci, A; Merli, F; Orsucci, L.; Cervetti, G; Occhini, U; Liberati, Anna Marina

Preoperative MUCP and VLPP failed to predict outcome in patients who underwent transobturator mid-urethral slings

2008 Costantini, Elisabetta; Lazzeri, Massimo; Giannantoni, Antonella; Bini, Vittorio; Mearini, Luigi; Zucchi, Alessandro; Porena, Massimo

Titolo	Data di pubblicazione	Autore(i)
Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-Cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open-label phase II trial.	2004	Morschhauser, F; Huglo, D; Martinelli, G; Paganelli, G; Zinzani, Pl; Hadjiyiannakis, D; Liberati, Anna Marina; Et, All
Improved safety profile of tumor-targeted taxane: an integrated safety summary of paclitaxel poliglumex (CT-2103) phase 1 and 2 trials	2004	P., Barbieri; F., Oldham; J., Holman; Liberati, Anna Marina
Features of relapsed disease in lymphocyte predominant Hodgkin's disease patients	2005	Liberati, Anna Marina; Cerroni, P; Zanotti, R; Spina, M; Viviani, S; Cervetti, G; Stelitano, C; Ferrara, P; Merluzzi, M; Vitolo, U.
Pre-autologous stem cell transplantation (ASCT) treatment with rituximab does not impair stem cell harvest and engraftment in untreated patients with diffuse large B-cell lymphoma (B-DLCL) at poor prognosis	2005	Botto, B; Vitolo, U; Cortelazzo, S; Chiappella, A; Allione, B; Angelucci, E; Boccomini, C; Cabras, Mg; Ceccarelli, M; Ciccone, G; Di Vito, F; Falchi, L; Guarini, A; Liberati, Anna Marina
Molecular response of CML patients to INF alpha based treatment or to STI based therapy.	2005	Luzi, D; Capozzi, R; Rauco, A; Pace, R; Donti, E; Gottardi, E; Bassetti, A.; Schippa, M; Saglio, G; Liberati, Anna Marina
Ph '-positive (Ph '+) chronic myeloid leukemia (CML) presenting as Ph ' plus T-lymphoblastic lymphoma (LL) resistant to high-dose chemotherapy and Gleevec.	2005	Falchi, L; Desantis, G.; Liberati, F; Pace, R; Morandi, Mg; Scaravaglio, P; Saglio, G; Liberati, Anna Marina
A continous recurrent course in a case of nodular-sclerosis (NS) classical Hodgkin's lymphoma (cHL) associated with Castleman's disease (CD)	2005	Rauco, A; Liberati, F; Capozzi, R; Morandi, Mg; Pace, R; Capparella, V; Cianciulli, M; Liberati, Anna Marina
Has the Ga-67-SPET a role in monitoring Hodgkin and primary mediastinal lymphoma in the PET-FDG age?	2005	Palumbo, Isabella; Desantis, G; Palumbo, Barbara; Falchi, L; Cerroni, P; Capparella, V; Cianciulli, M; Palumbo, R; Liberati, Anna Marina
Effect of adding Rituximab (R) to induction treatment and high dose chemotherapy (HDC) prior to autologous stem cell transplantation (ASCT) as first line therapy in stage III-IV diffuse large B-cell lymphoma (B-DLCL) at poor prognosis	2005	Vitolo, U; Rossi, G; Cabras, Mg; Liberati, Anna Marina
Rituximab-supplemented high-dose sequential chemotherapy (HDS) has superior response rate and event-free survival (EFS) compared to R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: Results from a multicenter randomized GITMO trial.	2005	Ladetto, M; Ricca, I; Benedetti, F; Vitolo, U; Patti, C; Rambaldi, A; Liberati, Anna Marina; Et, All
Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)	2005	F., Morschhauser; D., Huglo; G., Martinelli; G., Paganelli; P., Zinzani; D., Hadjiyiannakis; Liberati, Anna Marina; T., Illidge; N., Milpied; J., Kalmus; P., Morel; U., Reimann; R., Marcus
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) regimen as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi (gisl)	2005	N. D., Renzo; M., Brugiatelli; A., Montanini; M., Dell'Olio; M., Petrini; C., Stelitano; Liberati, Anna Marina; S., Luminari; S., Morandi; G., Giglio; M., Federico
Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with Rituximab as frontline therapy for high-risk follicular lymphoma (FL) patients: An interim analysis.	2002	Ladetto, M; Ricca, I; Benedetti, F; Vitolo, U; Liberati, Anna Marina; Et, All
Phase II study with Fludarabine and Cyclophosphamide plus Rituximab (FC plus R) in relapsed follicular lymphoma patients	2002	Sacchi, S; Tucci, A; Merli, F; Orsucci, L; Cervetti, G; Occhini, U; Liberati, Anna Marina
Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with rituximab in poor-risk follicular lymphoma: early evaluation on treatment feasibility and response rate	2003	Ladetto, M; Ricca, I; Benedetti, F; Liberati, Anna Marina
Acute myeloid leukemia in the elderly, intensive or maintenance therapy? Our experience in patients over 65 years.	2005	Mettivier, V; Pezzullo, L; Rocco, S; Finizio, O; Bene, L.; De Rosa, C; Nunziata, Gr; Liberati, Anna Marina
Anagrelide treatment and cardiovascular evaluation in 130 patients with essential thrombocythemia (ET): Preliminary report of the Registro Italiano Trombocitemia (RIT).	2005	Gugliotta, L; Tieghi, A; Bulgarelli, S; Tortorella, C; Ciancia, R; Scalzulli, Pr; Cacciola, E; Cacciola, R; Rossi, D; Usala, E; Crugnola, M; Candoni, A.; Giordano, M; Andriani, A; Santoro, C; Vimercati, R; Liberati, Anna Marina; Et, All
Comparative trial of BBR 2778 (pixantrone) plus rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).	2006	Santoro, A; Voglova, J; Gabrail, N; Ciuleanu, T; Liberati, Anna Marina
Rituximab (R) in combination with fludarabine (F) and cyclophosphamide (C) in relapsed follicular lymphoma (FL) patients (pts). Final results of FC plus R phase II trial by the GISL.	2006	Sacchi, S; Pozzi, S; Marcheselli, R; Luminari, S; Federico, M; Tucci, A; Merli, F; Orsucci, L.; Cervetti, G; Occhini, U; Liberati, Anna Marina
Preoperative MUCP and VLPP failed to predict outcome in patients who underwent transobturator mid-urethral slings	2008	Costantini, Elisabetta; Lazzeri, Massimo; Giannantoni, Antonella; Bini, Vittorio; Mearini, Luigi; Zucchi, Alessandro; Porena, Massimo

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 1.201 a 1.220 di 2.363

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext2363

IRIS - Res&Arch Institutional Research Information System - Research & Archive